

MVT *in* Silico

A life sciences innovation company.

London Ontario, Canada.

Presenters.

Dr. SR Kharche, CEO & CSO.

Ms Harpreet Kaur. Business Manager.

Mr. Yihang Cheng. R&D Support Officer.

Owner & President.

Sanjay R KHARCHE.

Ph.D.

CEO.

sumus@mvtinsilico.ca


5198780685.

London, Canada.

?


Problem.

Life sciences
(MedTech & BioTech)
innovation faces many hurdles,
limits tech translation.
Present industry capacity is
fragmented, insufficient.



Solution.

A CM&S approach tackles problems early, reduces costs considerably, informed product development, ...





Solution.

MVT *in Silico*'s two part proprietary platform addresses the industry's pain points, is designed for innovation as a routine.

CRO solutions, internal innovation programs.

Validation stage!

Computer experiments:
mvt
Software Suite.

In vitro experiments:
mvt
NAMs.

✓
1.
Dev efficiency.

- 60% reduction in materials/animal use.
- Shorter timelines limit personnel costs.
- Other savings.

✓
2.
Shorter dev cycles.

50% shorter timelines from design to prototype, weeks to months.

✓
3.
Improved success rates.

Platform generated evidence feeds into patent applications.

Business model.

**Diverse
relationships
impart
resilience,
channel our
innovation to
assets, provide
routes for our
public service.**



Competitive advantages.

MVTiS has many advantages.

We are a one stop shop for solutions to a wide spectrum of hard to solve problems in the life sciences.

● MedTech. ● BioTech.

	CFD Life (Japan).	Computational Life (Italy).	Intrepid labs, Toronto.	StokedBio, Hamilton.	MVT in Silico. Canada.
	●	●	●	●	● ●
Synthetic data.	✓	✓	✓	✓	✓
In vitro data.			✓		✓
Toxicity/ Failure opt.			✓	✓	✓
Device opt.	✓	✓			✓
Drug opt.			✓	✓	✓
Knowledge driven AI.	✓	✓	✓	✓	✓

● MedTech.
● BioTech.

Revenue streams.

Targeting high value, high impact markets.

Our mission is to address hard to
solve technological problems.

Specializations & ongoing projects.

DDS.



Blood flow
disorders.



Hormonal
disorders.



Molecular
& genetic
defects.



Target markets.

Women's
health.
(> \$50B).

Hypertension.
(> \$20B).

Rare
diseases &
orphan
drugs.
(societal
impact).

Team.

**An expert team
poised for
success,
additional skill
sets upcoming.**



Dr. Sanjay Kharche.
Founder, CEO, CSO.



Prof. D. G. Welsh.
Advisor. Pharmacology
expert.

CFO.
*Under
negotiation.*

IP expert.
*Under
negotiation.*

**Marketing &
sales.**
*Under
negotiation.*



Harpreet Kaur.
Business strategy
manager.




Yihang Cheng.
R&D officer.

Progress.

Milestones: Past & future.

Adopting a lean approach,
there is steady progress with
revenue expected in Q2 2026.




Ask and purpose.

**An investment opportunity:
We are raising \$1.5M, and leverage it to \$3M.**

With a runway to Q4 2027 (scheduled next raise), your \$\$ ensure expansion, a large ROI, and puts us together on a growth & profit trajectory!

Friday, May 23, 2025

2.4% each for fractional CFO, marketing & sales, IP professional, business support.



Other: Accounting, payroll, travel, training, misc.

Tech salaries
(31.3%).

Tech support
(6.6%).

Corporate legal
(6.6%).

Lab set up
(6.6%).

IP & legal
(13.3%).

Lab
equipment
(13.3%).

MVT in Silico.

10